As filed with the Securities and Exchange Commission on March 1, 2022
Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Epizyme, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 26-1349956 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
400 Technology Square, 4th Floor Cambridge, MA |
02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
2013 Stock Incentive Plan
2013 Employee Stock Purchase Plan
Inducement Stock Option Awards (August 2021-November 2021)
Inducement Restricted Stock Unit Awards (August 2021-November 2021)
(Full title of the plan)
Grant Bogle
President and Chief Executive Officer
Epizyme, Inc.
400 Technology Square, 4th Floor
Cambridge, MA 02139
(Name and address of agent for service)
(617) 229-5872
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
(Do not check if a smaller reporting company) |
||||||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 2,500,000 shares of the Registrants common stock, $0.0001 par value per share (Common Stock), to be issued under the Registrants 2013 Stock Incentive Plan (the 2013 Stock Incentive Plan), (ii) an additional 233,333 shares of Common Stock, to be issued under the Registrants 2013 Employee Stock Purchase Plan (the 2013 Employee Stock Purchase Plan) and (iii) 248,366 shares of Common Stock issuable upon exercise of stock options and 106,955 shares of Common Stock issuable upon vesting of restricted stock units granted to employees of the Registrant as an inducement material to entry into employment with the Registrant, in accordance with Nasdaq Listing Rule 5635(c)(4). Pursuant to General Instruction E to Form S-8, and only with respect to the Common Stock being registered under the 2013 Stock Incentive Plan and the 2013 Employee Stock Purchase Plan, this Registration Statement incorporates by reference the contents of the registration statement on Form S-8, File No. 333-189629, filed by the Registrant on June 27, 2013, relating to the Registrants 2008 Stock Incentive Plan, 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan; the registration statement on Form S-8, File No. 333-194205, filed by the Registrant on February 28, 2014, relating to the Registrants 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan; the registration statement on Form S-8, File No. 333-202681, filed by the Registrant on March 12, 2015, relating to the Registrants 2013 Stock Incentive Plan; the registration statement on Form S-8, File No. 333-210028, filed by the Registrant on March 9, 2016, relating to the Registrants 2013 Stock Incentive Plan; the registration statement on Form S-8, File No. 333-216638, filed by the Registrant on March 13, 2017, relating to the Registrants 2013 Stock Incentive Plan; the registration statement on Form S-8, File No. 333-223612, filed by the Registrant on March 13, 2018, relating to the Registrants 2013 Stock Incentive Plan; the registration statement on Form S-8, File No. 333-229878, filed by the Registrant on February 26, 2019, relating to the Registrants 2013 Stock Incentive Plan; the registration statement on Form S-8, File No. 333-236707, filed by the Registrant on February 27, 2020, relating to the Registrants 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan; and the registration statement on Form S-8, File No. 333-253383, filed by the Registrant on February 23, 2021, relating to the Registrants 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan; in each case except (x) to the extent superseded hereby and (y) for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.
The information required by Item 1 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the Securities Act).
- 2 -
Item 2. Registrant Information and Employee Plan Annual Information.
The written statement required by Item 2 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the Commission). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:
(a) The Registrants latest annual report filed pursuant to Section 13(a) or 15(d) of the Exchange Act or the latest prospectus filed pursuant to Rule 424(b) under the Securities Act that contains audited financial statements for the Registrants latest fiscal year for which such statements have been filed.
(b) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the document referred to in (a) above.
(c) The description of the securities contained in the Registrants registration statement on Form 8-A filed under the Exchange Act, including any amendment or report filed for the purpose of updating such description.
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Wilmer Cutler Pickering Hale and Dorr LLP has opined as to the legality of the securities being offered by this registration statement.
- 3 -
Item 6. Indemnification of Directors and Officers.
Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The registrants certificate of incorporation provides that no director shall be personally liable to the registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.
Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.
The registrants certificate of incorporation provides that it will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of the registrant) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the registrants request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the registrants best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
The registrants certificate of incorporation also provides that it will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the registrant to procure a judgment in the registrants favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the registrants request as a director, officer, partner, employee or trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she
- 4 -
reasonably believed to be in, or not opposed to, the registrants best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
The registrant has entered into indemnification agreements with its directors and executive officers. In general, these agreements provide that the registrant will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of the registrant or in connection with their service at the registrants request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer.
The registrant maintains a general liability insurance policy that covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
- 5 -
Filed herewith Item 9. Undertaking. 1. Item 512(a) of
Regulation S-K. The undersigned registrant hereby undertakes: (1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by
Section 10(a)(3) of the Securities Act; (ii) To reflect in the prospectus any facts or events arising after the effective date of
the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement; provided, however, that paragraphs (i) and (ii) do not apply if the
information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are
incorporated by reference in the registration statement. (2) That, for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering. - 6 -
2. Item 512(b) of Regulation S-K. The undersigned
registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated
by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
3. Item 512(h) of Regulation S-K. Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or
paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. - 7 -
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of
Massachusetts, on this 1st day of March, 2022. /s/ Grant Bogle - 8 -
POWER OF ATTORNEY AND SIGNATURES We, the undersigned officers and directors of Epizyme, Inc., hereby severally constitute and appoint Grant Bogle and John Weidenbruch, our true and lawful
attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent
amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Epizyme, Inc. to comply with the provisions of the Securities Act of 1933, as
amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. Signature Title Date /s/ Grant Bogle /s/ Joseph Beaulieu /s/ Roy A. Beveridge /s/ Kenneth Bate /s/ Kevin T. Conroy /s/ Michael F. Giordano /s/ Carl Goldfischer /s/ Pablo Legorreta /s/ David M. Mott /s/ Victoria Richon /s/ Carol Stuckley
*
EPIZYME, INC.
By:
Grant Bogle
President and Chief Executive Officer
President, Chief Executive Officer, Director
March 1, 2022
Grant Bogle
(Principal Executive Officer and Principal Financial Officer)
Corporate Controller and Treasurer
March 1, 2022
Joseph Beaulieu
(Principal Accounting Officer)
Director
March 1, 2022
Roy A. Beveridge
Director
March 1, 2022
Kenneth Bate
Director
March 1, 2022
Kevin T. Conroy
Director
March 1, 2022
Michael F. Giordano, M.D.
Director
March 1, 2022
Carl Goldfischer, M.D.
Director
March 1, 2022
Pablo Legorreta
Director
March 1, 2022
David M. Mott
Director
March 1, 2022
Victoria Richon, Ph.D.
Director
March 1, 2022
Carol Stuckley
Exhibit 5.1
March 1, 2022
Epizyme, Inc.
400 Technology Square
Cambridge, MA 02139
Re: | 2013 Stock Incentive Plan, 2013 Employee Stock Purchase Plan, Inducement |
Stock Option Awards (August 2021-November 2021) and Inducement Restricted
Stock Unit Awards (August 2021-November 2021)
Ladies and Gentlemen:
We have assisted in the preparation of a Registration Statement on Form S-8 (the Registration Statement) to be filed with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended (the Securities Act), relating to (i) an aggregate of 2,733,333 additional shares of common stock, $0.0001 par value per share (the Plan Shares), of Epizyme, Inc., a Delaware corporation (the Company), issuable under the Companys 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan (collectively, the Plans), (ii) an aggregate of 248,366 shares of Common Stock (the Option Shares) issuable pursuant to inducement stock option agreements providing for employee inducement stock option grants between the Company and various employees, which were entered into in connection with the entry into such employees employment with the Company pursuant to Nasdaq Stock Market Rule 5635(c)(4) (collectively, the Inducement Option Agreements) and (iii) an aggregate of 106,955 shares of Common Stock (the RSU Shares, and collectively with the Plan Shares and Option Shares, the Shares) issuable pursuant to inducement restricted stock unit agreements providing for employee inducement restricted stock unit grants between the Company and various employees, which were entered into in connection with the entry into such employees employment with the Company pursuant to Nasdaq Stock Market Rule 5635(c)(4) (collectively with the Inducement Option Agreements, the Inducement Award Agreements).
We have examined the Restated Certificate of Incorporation, as amended, and the Amended and Restated By-Laws of the Company and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the directors and stockholders of the Company, the Registration Statement and such other documents relating to the Company as we have deemed material for the purposes of this opinion.
In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.
We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans or the Inducement Award Agreements, as applicable, to register and qualify the Shares for sale under all applicable state securities or blue sky laws.
We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of The Commonwealth of Massachusetts, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.
It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plans, the Shares will be validly issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
Very truly yours, | ||
WILMER CUTLER PICKERING HALE AND DORR LLP | ||
By: | /s/ Stuart M. Falber | |
Stuart M. Falber, Partner |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2013 Stock Incentive Plan, 2013 Employee Stock Purchase Plan, Inducement Stock Option Awards (August 2021-November 2021) and the Inducement Restricted Stock Unit Awards (August 2021-November 2021) of Epizyme, Inc. of our reports dated March 1, 2022, with respect to the consolidated financial statements of Epizyme, Inc. and the effectiveness of internal control over financial reporting of Epizyme, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 1, 2022
Exhibit 107
Calculation of Filing Fee Tables
Form S-8 |
(Form Type) |
Epizyme, Inc. |
(Exact Name of Registrant as Specified in its Charter) |
Table 1Newly Registered Securities
Security Type | Security Class Title |
Fee Calculation Rule |
Amount Registered (1) |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 2,733,333 shares(2) | $1.41(3) | $3,854,000(3) | $92.70 per $1,000,000 |
$357.27 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 42,500 shares(4) | $5.31(5) | $225,675(5) | $92.70 per $1,000,000 |
$20.93 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 37,500 shares(4) | $5.31(5) | $199,125(5) | $92.70 per $1,000,000 |
$18.46 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 125,866 shares(4) | $5.19(5) | $653,244.54(5) | $92.70 per $1,000,000 |
$60.56 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 42,500 shares(4) | $4.44(5) | $188,700(5) | $92.70 per $1,000,000 |
$17.50 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 28,333 shares(6) | $1.41(3) | $39,949.53(3) | $92.70 per $1,000,000 |
$3.71 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 25,000 shares(6) | $1.41(3) | $35,250(3) | $92.70 per $1,000,000 |
$3.27 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 25,289 shares(6) | $1.41(3) | $35,657.49(3) | $92.70 per $1,000,000 |
$3.31 | |||||||
Equity | Common Stock, $0.0001 par value per share | Other | 28,333 shares(6) | $1.41(3) | $39,949.53(3) | $92.70 per $1,000,000 |
$3.71 | |||||||
Total Offering Amounts | $585,727.90 | $488.72 | ||||||||||||
Total Fee Offsets | $ | |||||||||||||
Net Fee Due | $488.72 |
(1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) | Represents an automatic annual increase on January 1, 2022 to the number of shares reserved for issuance under the 2013 Stock Incentive Plan and the 2013 Employee Stock Purchase Plan and consists of (i) 2,500,000 additional shares issuable under the 2013 Stock Incentive Plan and (ii) 233,333 additional shares issuable under the 2013 Employee Stock Purchase Plan. |
(3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $1.41, the average of the high and low price of the Registrants Common Stock as reported on the Nasdaq Global Select Market on February 24, 2022. |
(4) | Consists of shares of Common Stock issuable under new hire inducement stock option awards granted between August 16, 2021 and November 1, 2021 to certain employees of the registrant as an inducement material to entry into employment with the registrant in accordance with Nasdaq Listing Rule 5635(c)(4). |
(5) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated based on the exercise price of the options outstanding under the applicable inducement stock option awards. |
(6) | Consists of shares of Common Stock issuable under new hire inducement restricted stock unit awards granted between August 16, 2021 and November 1, 2021 to certain employees of the registrant as an inducement material to entry into employment with the registrant in accordance with Nasdaq Listing Rule 5635(c)(4). |